Ibogaine for Health & Longevity - Quick Reference Sheet

Ibogaine for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Ibogaine, a plant-derived compound given as a single, long, dream-like session, is studied for addiction, trauma-related conditions and brain injury. Human evidence for benefit is modest, from small studies without comparison groups; none addresses lifespan. The main risk is well documented: sometimes fatal heart-rhythm disturbances, magnified by other drugs and genetics. The data are too limited to establish clinical use. (Full Review)

Protocol

Stanford magnesium-ibogaine protocol
2–3 mg/kg test dose, then up to under 14 mg/kg within 2 hours
8-hour fast; further doses after about 40 minutes; intravenous magnesium; 12–16 hours of ECG monitoring
Dutch inpatient protocol
Morphine conversion, then a single 10 mg/kg dose
At least 24 hours of monitoring of QTc, blood pressure, ataxia and delirium
Repeated fixed-dose approach
100 mg doses, up to 600 mg
Stepwise as withdrawal returned, to taper methadone
Time to effect
Trauma, mood and anxiety symptoms
4–5 days and one month
Psychiatric scale improvements; uncontrolled
Opioid withdrawal
Within about 76 hours
Withdrawal scores fell; unreplicated
Cognition, sleep, post-concussion symptoms
One month
Self-reported; uncontrolled

Benefits

Contraindications
  • Congenital or acquired long QT syndrome, family history of sudden cardiac death, or resting QTc above 420 ms
  • Structural or ischemic heart disease, heart failure, arrhythmias, or syncope of unknown cause
  • Resting heart rate below 50 beats per minute, or blood pressure at or above 160/100 mmHg
  • Uncorrected hypokalemia or hypomagnesemia
  • Personal or first- or second-degree family history of psychosis, bipolar disorder or schizophrenia
  • Seizure history, or recent alcohol or benzodiazepine dependence without medically managed withdrawal
  • Liver or kidney disease; pregnancy or lactation; active suicidal ideation
  • CYP2D6 poor metabolizers at standard doses (some protocols exclude poor and ultra-rapid metabolizers)
  • Anyone taking interacting drugs that cannot be safely stopped
  • QT-prolonging drugs (methadone, citalopram, haloperidol); CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion)
  • Serotonin-raising drugs (sertraline, tramadol) and supplements (St. John's wort, 5-hydroxytryptophan)
  • Diuretics (furosemide) and corticosteroids (prednisone)
  • Stimulants (amphetamine, methylphenidate) and stimulant supplements (yohimbine, synephrine, high-dose caffeine)
  • Licorice root; kratom (mitragynine)
Key Interactions
  • Beta-blockers (metoprolol, propranolol) and calcium-channel blockers (verapamil, diltiazem)
  • Opioids (heroin, oxycodone, buprenorphine)
  • Benzodiazepines (diazepam, alprazolam) and alcohol
  • QT- or CYP2D6-active products (loperamide at high doses, diphenhydramine, dextromethorphan, cimetidine)
  • Decongestants (pseudoephedrine, phenylephrine)
  • Cannabidiol and berberine; magnesium and potassium (monitor)
  • Other psychedelics (psilocybin, 5-MeO-DMT)
  • Grapefruit and Seville orange; fasting, dehydration and heat exposure

Risk & Side Effects

  • High: QT Prolongation, Arrhythmia and Sudden Cardiac Death; Nausea, Vomiting and Headache; Cerebellar Ataxia and Tremor
  • Medium: Acute Anxiety, Agitation and Insomnia; Blood Pressure Elevation
  • Low: Overdose Risk After Stopping Maintenance Medication; Persistent Psychiatric Effects, Including Mania; Seizures; Visual Disturbance and Transient Confusion
  • Speculative: Cerebellar Neuron Loss

Monitoring

Marker Target Why
Resting QTc (12-lead ECG) At or below 420 ms Arrhythmia risk
Heart rate 55–80 beats per minute Bradycardia risk
Blood pressure Below 120/80 mmHg Hypertension around dosing
Serum potassium 4.0–5.0 mmol/L Torsades risk
Serum magnesium 2.0–2.5 mg/dL QT protection
Serum calcium 9.2–10.0 mg/dL QT effect of low calcium
ALT and AST ALT and AST both below 25 U/L Liver clearance
eGFR Above 90 mL/min/1.73 m² Kidney clearance
CYP2D6 genotype No established target; record phenotype Sets exposure and dose
Urine drug screen Negative for non-prescribed substances Interactions, withdrawal seizures

Cadence: Baseline before any dosing; continuous ECG and blood pressure from dosing through at least 24 hours; electrolytes at dosing and again 12–24 hours later; symptoms and function at 4–5 days and 1 month, then every 3–6 months

Qualitative Assessment

  • Craving intensity and withdrawal comfort
  • Mood, anxiety and trauma-symptom scores on validated questionnaires
  • Sleep quality and duration
  • Cognitive clarity, concentration and processing speed
  • Gait and coordination recovery within 24 hours
  • Energy and daily functioning
  • Substance-use days and relapse triggers